Browsing Tag
LB-100
2 posts
Could PP2A-targeted immunotherapy combinations improve outcomes in ovarian clear cell carcinoma?
Could PP2A-targeted immunotherapy reshape ovarian cancer treatment and Lixte’s valuation story? Read the executive analysis on what changes next.
LIXTE Biotechnology commences Phase 1b/2 clinical trial in ovarian cancer
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) has initiated a pivotal Phase 1b/2 clinical trial, in partnership…